CLLS - Cellectis S.A.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
http://www.cellectis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees161

Key Executives

NameTitlePayExercisedYear Born
Dr. André ChoulikaCo-Founder, Chairman & CEON/AN/A1965
Dr. David J. D. SourdiveCo-Founder, Deputy CEO, Exec. VP of Strategic Initiatives & DirectorN/AN/A1967
Mr. Eric DutangChief Financial OfficerN/AN/A1974
Mr. Jean Charles EpinatChief Technological OfficerN/AN/AN/A
Mr. Stephan ReynierChief Regulatory & Compliance OfficerN/AN/A1969
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.

Corporate Governance

Cellectis S.A.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.